Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Collaborators (239)

Cummings S, Christiansen C, Delmas P, Eastell R, McClung M, Reid I, Siris E, Aqua K, Lee E, Boling E, Bolognese M, Burch F, Cohen S, Fiske D, Petit C, Pierson M, Garrison K, Gallup E, Geisberg H, Hassman D, Helfrich D, Krohn K, Cuevas E, Larson W, Seiler J, Lederman S, Lewiecki M, MacCarter D, McClung M, Miller P, Moffett A Jr, Recknor C, Simon J, Trapp R, Woodson G 3rd, Bone H, Murtaugh T, Ruckle J, Wasnich R, Gallagher C, Dhillon G, Feldman R, Pennington G, Saxe P, Goldberg C, Rogers K, Keller M, Swor M, Rosen A, Stjernholm M, Adachi J, Brown J, Faraawi R, Kendler D, Kremer R, Olszynski W, Yuen CK, McKendry R, Boudreau J, Man Z, Zanchetta J, Mautalen C, de Gregorio L, Eis S, Radominski S, da Silva N, Griz L, Provenza J, Zerbini C, García-Hernández P, Araujo-Arias M, Bueno E, Fuentes-Cantu A, Perez M, Balderas-Acata J, Avila-Armengol H, de la Peña-Rodríguez M, Nicholson G, Ebeling P, Sambrook P, Hooper M, Prins J, Russell A, Reid I, Gilchrist N, Preisinger E, Resch H, Fahrleitner-Pammer A, Huber J, Kudlacek S, Reginster JY, Kaufman JM, Boonen S, Body JJ, Devogelaer JP, Tegibjearg C, Juel R, Alexandersen P, Hoeck HC, Jensen JE, Välimäki M, Salmi J, Delmas P, Fardellone P, Weryha G, Benhamou CL, Maugars Y, Roux C, Stahl HD, Blome-Henning U, Lochman B, Kopsch U, Roitenberg A, Adami S, Brandi M, Minisola S, Bianchi G, Sinigaglia L, Frediani B, Marcolongo R, Fiore C, Nuti R, Realdi G, Dijkmans B, Laan R, Bruyn G, Deijl A, Meesters E, Lems W, Verhage A, van de Walle V, Halse J, Hoiseth A, Syversen U, Stakkestad J, Minguella J, Mola E, Torres M, Gómez J, Hawkins F, Román J, Alvaro-Gracia J, Del Pino J, Palacios S, Ljunggren O, Toss G, Samsioe G, Mellström D, Löfgren J, Törring O, Lippuner K, Krieg MA, Uebelhart D, Eastell R, Thomas H, Shaw H, Donnachie H, Pavel-Knox I, Robinson J, Kola N, Sarmiento R, Pawa R, Savani N, Kucerova I, Kuba V, Vyskocil V, Kutilek S, Novosad P, Slesinger J, Dokoupilova E, Doubravsky J, Gorgol J, Pavelka K, Valter I, Maasalu K, Kull I, Phenekos C, Lyritis G, Dimitriadis A, Spengler B, Insperger A, Balázs T, Lakatos P, Takács K, Szombati I, Tarján K, Valkusz Z, Torma O, Seregely K, Kaze I, Lejnieks A, Medne A, Tamulaitiene M, Velickiene D, Stonkus S, Brincat M, Walecki J, Bykowska M, Sidorowicz-Bialynicka A, Szechinski J, Korkosz M, Supronik J, Koziara M, Czerwinski E, Milewicz A, Jeka S, Kania G, Gidzinski P, Sawicki A, Tlustochowicz W, Franek E, Hoszowski K, Pluskiewicz W, Porawska W, Zgliczynski W, Killinger Z, Masaryk P, Kmecova Z, Tomkova S, Spustova V, Steno B, Zbranca E, Codreanu C, Hristov V, Russev T, Ivanova AM, Velev R, Mitkov M, Troev D, Brankovic S, Dimic A, Pilipovic N, Hlatky M, Goldschlager N, Herrington D, Ryan C, Migliorati C, Ruggiero S, Schubert M.

Author information

  • 1San Francisco Coordinating Center, California Pacific Medical Center Research Institute and University of California, San Francisco, San Francisco, CA, USA. hglicklandes@sfcc-cpmc.net

Erratum in

  • N Engl J Med. 2009 Nov 5;361(19):1914.

Abstract

BACKGROUND:

Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of osteoclasts, decreasing bone resorption, and increasing bone density. Given its unique actions, denosumab may be useful in the treatment of osteoporosis.

METHODS:

We enrolled 7868 women between the ages of 60 and 90 years who had a bone mineral density T score of less than -2.5 but not less than -4.0 at the lumbar spine or total hip. Subjects were randomly assigned to receive either 60 mg of denosumab or placebo subcutaneously every 6 months for 36 months. The primary end point was new vertebral fracture. Secondary end points included nonvertebral and hip fractures.

RESULTS:

As compared with placebo, denosumab reduced the risk of new radiographic vertebral fracture, with a cumulative incidence of 2.3% in the denosumab group, versus 7.2% in the placebo group (risk ratio, 0.32; 95% confidence interval [CI], 0.26 to 0.41; P<0.001)--a relative decrease of 68%. Denosumab reduced the risk of hip fracture, with a cumulative incidence of 0.7% in the denosumab group, versus 1.2% in the placebo group (hazard ratio, 0.60; 95% CI, 0.37 to 0.97; P=0.04)--a relative decrease of 40%. Denosumab also reduced the risk of nonvertebral fracture, with a cumulative incidence of 6.5% in the denosumab group, versus 8.0% in the placebo group (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01)--a relative decrease of 20%. There was no increase in the risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia, and there were no cases of osteonecrosis of the jaw and no adverse reactions to the injection of denosumab.

CONCLUSIONS:

Denosumab given subcutaneously twice yearly for 36 months was associated with a reduction in the risk of vertebral, nonvertebral, and hip fractures in women with osteoporosis. (ClinicalTrials.gov number, NCT00089791.)

2009 Massachusetts Medical Society

Comment in

PMID:
19671655
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Atypon
    Loading ...
    Write to the Help Desk